Retrophin ups guidance

|By:, SA News Editor

Citing robust reimbursement for Chenodal and success in finding undiagnosed cerebrotendinous xanthomatosis (CTX) patients, Retrophin (RTRX) ups its guidance for 2014 and 2015 to $19M - $21M (up from $10 - $12M) and $35M - $40M (up from $19M - $21M), respectively.

The FDA declines to approve a clinical trial for RE-024 through an investigator-sponsored IND. The company will file its own by mid-year for pantothenate kinase-associated neurodegeneration (PKAN) patients.

Phase 3 clinical trial for RE-034 to start in Q3.